The strong Q3 earnings report, driven by significant revenue from HEPZATO and CHEMOSAT, indicates positive financial health and growth potential for Delcath Systems. The company's plans to expand its commercial footprint and explore new cancer indications and label expansions are likely to drive further growth, making the stock attractive in the short term.